Jaydip Deb

Jaydip Deb

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2013 in The Journal of Obstetrics and Gynecology of India
Verified
Journal Article
Closed access
PDF file
SBSoumya Bhattacharjee
Soumya Bhattacharjee
JDJaydip Deb
Jaydip Deb
RSRama Saha
Rama Saha
SCSudipta Chakrabarti
Sudipta Chakrabarti
JMJoydev Mukherji
Joydev Mukherji
STSumit Roy Tapadar
Sumit Roy Tapadar

3 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PVPankaj Vyas
Pankaj Vyas
MCMitul Chaudhari
Mitul Chaudhari
JDJaydip Deb
Jaydip Deb
ABAmit Bhate
Amit Bhate
MJManish Jain
Manish Jain
HPHardik Pathak
Hardik Pathak
Background A novel fixed-dose combination of vilanterol 25-µg, umeclidinium 62.5-µg, and fluticasone furoate 200-µg (VIL-UME-FF) in dry powder inhaler (DPI) was developed by M/s. Zydus Healthcare Limited for managing persistent asthma. Methods In this phase 3, multicenter, parallel group, open-label, randomized trial, patients received either test (VIL-UME-FF DPI) or reference DPI (indacaterol 150-µg, glycopyrronium 50-µg, and mometasone furoate 160-µg; IND-GLY-MF DPI). The primary endpoint was change from baseline in trough forced expiratory volume-1 (FEV1) at week-12. Secondary endpoints included trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test (ACT) score. Results A total of 258 participants (18-65 years) were enrolled (Test: 129; Reference: 129). The least square mean change in trough FEV1 at week-12 was 342.9 (21.3) ml for the test group and 327.6 (21.4) ml for the reference group (p=0.6141). The lower limit of 95% confidence interval for the difference between the groups was -44.19 ml, well-above the predefined non-inferiority margin (-150 ml). At week-12, trough FVC, post-bronchodilator FEV1 and FVC, and ACT scores were comparable between the study groups. Conclusion VIL-UME-FF DPI was non-inferior to IND-GLY-MF DPI in improving trough FEV1 and other efficacy parameters and was well-tolerated in Indian patients with persistent asthma.